| The COVID-19 trade is dead, folks. It’s time to get in place for the next massive trend in biotech investing. After mRNA vaccine pioneer Moderna Inc. (Nasdaq: MRNA) topped out at $497 this year, shares fell by more than half. And there’s no indication that the bleeding will stop. Moderna launched one of the first two COVID-19 vaccines late last year, and it seemed like the stock would soar for a long time. But after an earnings miss this past quarter and a spat with the government over vaccine patents, MRNA has lost its appeal. It’s not the only one. BioNTech SE (Nasdaq: BNTX), which collaborated with Pfizer Inc. (NYSE: PFE) to create the other groundbreaking mRNA vaccine, is trending in the wrong direction now as well. You can see how far MRNA and BNTX have plunged from their August highs in the chart below:  I don’t recommend “fighting the tape.” Momentum drives my investing strategy, and neither of these stocks is trending in the right direction. But don’t look away! I still believe that genomics — DNA-based science — represents the single biggest investment opportunity of our lifetimes. (Watch my presentation on this tech, which I call “Imperium,” to find out more.) That’s not hyperbole. When it comes to investment opportunities, I expect the genomics revolution to be more massive than cryptocurrencies, electric cars and even the internet itself.
| He bought Amazon when it was trading around $35... Netflix when it was around $2... And Apple when it was less than $1 a share... And now... Market millionaire Alexander Green says he's discovered the "Perfect Stock" that could be the key to boosting your retirement. | |
COVID-19 Vaccine Was the Spark I won’t be cavalier. A lot of people are still getting sick and even dying from COVID-19. And I take that seriously. As an act of decency to my fellow man, I think it’s important to try to avoid getting infected and spreading the virus. But as an investment theme, COVID-19 is done. Most of the adult population is vaccinated. Boosters may become an annual ritual, but that’s not a source of growth. It’s maintenance at best. This is why we see weakness in stocks like Moderna or BioNTech. But it’s also a case of investors putting far too much emphasis on the immediate short term. They fail to see the much bigger picture. The COVID-19 mRNA vaccines were a proof of concept for mRNA technology: It works, we can mass produce it, and it’s economically viable. The pipeline of potential therapies is almost unlimited. As cases in point, Moderna has promising mRNA treatments in the pipeline for cancer and HIV along with a flu vaccine that could hit the market as soon as 2023. That’s just the start.
| Get the name of the crypto that's growing 4X faster than Bitcoin. Billionaire Dallas Mavericks owner Mark Cuban is calling it a "game-changer." | |
The Next Step for Genomics Last month, I shared the table below with readers of my premium research service, Green Zone Fortunes. 
You can see the massive advances the technology has made in under 20 years. The cheaper it becomes, the more practical applications we’ll see. Think back to the early days of the internet. Data was expensive, and the speed was painful. Remember how long it took to dial into the internet using a modem on your home’s landline? But as communications costs dropped, new applications became the norm. Hailing an Uber or streaming a video on Netflix would have been impossible with data cost and speeds circa 1999. Today, we just expect it. Last month in Green Zone Fortunes, I recommended a leader in genetic testing technology. Like Moderna and BioNTech, the company rose to prominence during the pandemic, as people the world over needed access to cheap and effective COVID tests. But the story here is much bigger than COVID. The company used its pandemic windfall to fund the next major stage of its growth: Screening for cancer and for genetic-based diseases. And this stock is still well within my buyzone. In fact, I expect it to more than double in the next two years. To find out how you can gain access to this stock recommendation, along with other DNA science stock recommendations (including my No. 1 genomics stock), click here to watch my “Imperium” presentation now. You’ll learn why the genomics stock mega trend will be bigger than investing in internet stocks in the ‘90s. Click here to join us now! 
Adam O'Dell
Chief investment strategist, Money & Markets
Suggested Stories: Tesla ✔️ … Next Trillion-Dollar America 2.0 Company? Holiday Spending Spree Will Boost High-Momentum Clothing Stock
| 
1933: Nazi Germany withdrew from the League of Nations. | |
Privacy Policy
The Money & Markets, P.O. Box 8378, Delray Beach, FL 33482.
To ensure that you receive future issues of Money & Markets, please add info@mb.moneyandmarkets.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance.
The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: https://moneyandmarkets.com/contact-us/
Legal Notice: This work is based on what we've learned as financial journalists. It may contain errors and you should not base investment decisions solely on what you read here. It's your money and your responsibility. Nothing herein should be considered personalized investment advice. Although our employees may answer general customer service questions, they are not licensed to address your particular investment situation. Our track record is based on hypothetical results and may not reflect the same results as actual trades. Likewise, past performance is no guarantee of future returns. Certain investments carry large potential rewards but also large potential risk. Don't trade in these markets with money you can't afford to lose. Money & Markets expressly forbids its writers from having a financial interest in their own securities or commodities recommendations to readers. Such recommendations may be traded, however, by other editors, Money & Markets, its affiliated entities, employees, and agents, but only after waiting 24 hours after an internet broadcast or 72 hours after a publication only circulated through the mail.
(c) 2021 Money & Markets, LLC. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Money & Markets. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 800-684-8471)
Remove your email from this list: Click here to Unsubscribe | | | 
No comments:
Post a Comment